Ocumension Therapeutics (HKSE:01477) Additional Paid-In Capital : HK$8,290.1 Mil(As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Additional Paid-In Capital?

Ocumension Therapeutics's quarterly additional paid-in capital increased from Jun. 2023 (HK$8,147.7 Mil) to Dec. 2023 (HK$8,340.7 Mil) but then stayed the same from Dec. 2023 (HK$8,340.7 Mil) to Jun. 2024 (HK$8,290.1 Mil).

Ocumension Therapeutics's annual additional paid-in capital declined from Dec. 2021 (HK$9,006.5 Mil) to Dec. 2022 (HK$8,387.8 Mil) and declined from Dec. 2022 (HK$8,387.8 Mil) to Dec. 2023 (HK$8,340.7 Mil).

Ocumension Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Ocumension Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Additional Paid-In Capital Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

9,006.54

8,387.76

8,340.66

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial							-	8,387.76	8,147.74	8,340.66	8,290.06

Ocumension Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Ocumension Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

https://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Liu Ye	2101 Beneficial owner
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Chen Ziqing	2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p.	2101 Beneficial owner
Boyu Capital Fund Iv, L.p	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Ocumension Therapeutics Headlines

No Headlines